The shadow of generic challenges has long loomed above copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the future of similar drug portfolios. While initial times saw impressive returns, the exclusivity expiration has allowed the door for cheaper alternatives, possibly reducing revenue and creating a real danger for stakeholders